SCHEMBL564310

SCHEMBL564310

O=C1CC(c2cccc(Cl)c2)CN1

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 8/20 0.53
PDE4A P27815 8/20 0.51
PDE4B Q07343 4/20 0.51
PDE4C Q08493 4/20 0.51
PDE4D Q08499 4/20 0.51
ALDH1A1 P00352 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP2C19 P33261 1/20 0.51
SLC6A2 P23975 5/20 0.49
MTNR1A P48039 1/20 0.46
SLC6A4 P31645 1/20 0.46
TSHR P16473 1/20 0.44
TP53 P04637 1/20 0.43
MDM2 Q00987 1/20 0.43
VEGFA P15692 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31348863 0.83 LMNA (0.51) SLC6A3ALDH1A1SLC6A2SLC6A4TSHR
SCHEMBL29282151 0.80 PDE4A (0.51) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL30913207 0.80 PDE4A (0.51) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL29282146 0.80 PDE4A (0.51) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL16977975 0.80 PDE4A (0.51) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL30913190 0.80 PDE4A (0.51) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL11101873 0.80 PDE4A (0.51) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL21609303 0.80 PDE4A (0.51) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL20475360 0.80 PDE4A (0.51) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL1269222 0.80 PDE4A (0.55) PDE4APDE4BPDE4CPDE4DALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8492416-B2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2013-07-23 US disclosed
US-8492416-B2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2013-07-23 US disclosed
US-8492416-B2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2013-07-23 US disclosed
US-20120035239-A1 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB Biopharma SRL (BE) 2012-02-09 US disclosed
US-20120035239-A1 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB Biopharma SRL (BE) 2012-02-09 US disclosed
US-20120035239-A1 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB Biopharma SRL (BE) 2012-02-09 US disclosed
US-8034958-B2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UOB Pharma, S.A. (BE) 2011-10-11 US disclosed
US-8034958-B2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UOB Pharma, S.A. (BE) 2011-10-11 US disclosed
US-8034958-B2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UOB Pharma, S.A. (BE) 2011-10-11 US disclosed
US-20100222576-A1 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB BIOPHARMA SPRL (BE) 2010-09-02 US disclosed
US-6806287-B2 NEUROLOGICAL DISORDERS; SUCH AS 2-(4-(2,2-DIFLUOROVINYL)-2-OXOPYRROLIDINYL)BUTANAMIDE UCB, S.A. (BE) 2004-10-19 US disclosed
EP-1452524-A1 \"2-oxo-1-pyrrolidine derivative and its pharmaceutical uses\ UCB, S.A. (BE) 2004-09-01 EP disclosed
US-6784197-B2 SUCH AS (2S)-2-((4S)-4-(2,2-DIFLUOROVINYL)-2-OXOPYRROLIDINYL) BUTANAMIDE; ANTIEPILEPTIC AGENTS; ANTICONVULSANTS UCB S.A. (BE) 2004-08-31 US disclosed
EP-1447399-A1 \"2-oxo-1-pyrrolidine derivative and its pharmaceutical uses\ UCB, S.A. (BE) 2004-08-18 EP disclosed
US-20040116507-A1 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB Biopharma SRL (BE) 2004-06-17 US disclosed
US-20040087646-A1 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB BIOPHARMA SPRL (BE) 2004-05-06 US disclosed
US-20030120080-A1 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB Biopharma SRL (BE) 2003-06-26 US disclosed
CN-1404469-A 2-oxo-1-pyrrolidine derivatives, preparation method and use thereof UCB SA (BE) 2003-03-19 CN disclosed
EP-1265862-A2 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB, S.A. (BE) 2002-12-18 EP disclosed
WO-2001062726-A2 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB, S.A. (BE) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222576-A1 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses CYP1B1, OGDH, CYP1A2 SLC6A3 2687/4885PDE4A 698/4885PDE4B 548/4885
US-20120035239-A1 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES CYP1B1, OGDH, CYP1A2 SLC6A3 2687/4885PDE4A 698/4885PDE4B 548/4885
US-20030120080-A1 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses CYP1B1, CYP1A2, OGDH SLC6A3 2377/4885PDE4A 677/4885PDE4B 512/4885
US-20040087646-A1 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses CYP1B1, CYP1A2, OGDH SLC6A3 2490/4885PDE4A 723/4885PDE4B 585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.